230000000875 corresponding Effects 0.000 claims description 8.241000589517 Pseudomonas aeruginosa Species 0.000 claims description 9.229940055023 Pseudomonas aeruginosa Drugs 0.000 claims description 9.241000589875 Campylobacter jejuni Species 0.000 claims description 9.102000014914 Carrier Proteins Human genes 0.000 claims description 14.108010078791 Carrier Proteins Proteins 0.000 claims description 14.ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 16.108020004707 nucleic acids Proteins 0.000 claims description 17.150000007523 nucleic acids Chemical class 0.000 claims description 18.229920000453 Consensus sequence Polymers 0.000 claims description 18.229920003303 ion-exchange polymer Polymers 0.000 claims description 27.239000003456 ion exchange resin Substances 0.000 claims description 27.238000006467 substitution reaction Methods 0.000 claims description 36.150000004804 polysaccharides Polymers 0.000 claims description 42.239000005017 polysaccharide Substances 0.000 claims description 42.229920001282 polysaccharide Polymers 0.000 claims description 42.150000001413 amino acids Chemical class 0.000 claims description 52.102000037240 fusion proteins Human genes 0.000 claims description 128.108020001507 fusion proteins Proteins 0.000 claims description 128.125000003275 alpha amino acid group Chemical group 0.000 claims description 151.108090000623 proteins and genes Proteins 0.000 claims description 181.102000004169 proteins and genes Human genes 0.000 claims description 181.238000000746 purification Methods 0.000 claims abstract description 37.238000004255 ion exchange chromatography Methods 0.000 claims abstract description 37.238000001742 protein purification Methods 0.000 title abstract description 6.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from EP19183033.0 external-priority Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa Priority to JP2021576833A priority Critical patent/JP2022538580A/en Priority to BR112021026247A priority patent/BR112021026247A2/en Priority to CA3144291A priority patent/CA3144291A1/en Priority to EP20733843.5A priority patent/EP3990639A1/en Priority to US17/619,334 priority patent/US20220298205A1/en Priority to CN202080060307.4A priority patent/CN114341192A/en Publication of WO2020260436A1 publication Critical patent/WO2020260436A1/en Links Inventor Martin Edward Braun Amirreza Faridmoayer Sabina Marietta GERBER Christian Andreas LIZAK Gilles Martin Markus Daniel MÜLLER Original Assignee Glaxosmithkline Biologicals Sa Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents WO2020260436A1 - Methods for protein purification WO2020260436A1 - Methods for protein purification
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |